By blocking leukotriene signalling in the airways, Singulair tablets help reduce inflammation linked with asthma and allergic rhinitis. They are used for adults and children whose symptoms need regular prevention rather than sudden relief. This oral treatment can reduce wheeze, chest tightness, nasal blockage and allergy-related night symptoms when taken consistently.
Singulair contains montelukast sodium, a leukotriene receptor antagonist, also called an LTRA or leukotriene modifier. Leukotrienes are inflammatory chemicals released during allergic reactions. They can narrow airway muscles, increase mucus and contribute to nasal swelling.
Singulair is supplied as tablets for oral use. The dose is decided individually, taking age, other medicines and health conditions into account. Adults and children may require different montelukast tablet presentations, so the prescribed regimen should match the person receiving treatment.
For asthma, montelukast is commonly scheduled once daily, often in the evening because asthma symptoms can intensify overnight. For allergic rhinitis, the time of day may be adjusted around the person’s symptom pattern and routine. A clinician may choose a different strategy when asthma and rhinitis occur together.
Common administration errors include:
If a dose is missed, take the next scheduled dose at the usual time. Do not take two tablets together to compensate.
Singulair contains montelukast sodium, a leukotriene receptor antagonist (LTRA). It blocks leukotriene signalling, helping reduce airway inflammation, mucus-related symptoms and nasal swelling associated with asthma and allergic rhinitis.
Montelukast blocks the cysteinyl leukotriene receptor, known as CysLT1. This receptor sits on airway smooth muscle and inflammatory cells. When leukotrienes bind to it, the airway can tighten and produce more mucus.
Blocking that signal can reduce bronchoconstriction, airway swelling and allergy-related inflammation. The action differs from a bronchodilator, which relaxes airway muscles directly, and from an inhaled corticosteroid, which suppresses several inflammatory pathways inside the lungs.
Montelukast is an oral leukotriene receptor antagonist.
Singulair is used as maintenance treatment for asthma, including mild asthma when symptoms are linked with allergens, exercise or night-time airway inflammation. It may also be prescribed for seasonal allergic rhinitis and perennial allergic rhinitis. The tablets do not replace a quick-relief inhaler during an asthma attack.
The MHRA describes montelukast as a preventive treatment. It should not be relied on for sudden breathlessness, rapidly worsening wheeze or an acute asthma exacerbation. [1]
The most common clinical reasons for prescribing Singulair include:
Patients often notice that cough and chest tightness are worse at night or after exercise. These patterns can help a prescriber decide whether montelukast fits the asthma plan.
The biggest mistake is treating Singulair as a substitute for emergency asthma care. It works gradually on inflammatory signalling and cannot provide rapid bronchodilation during an attack.
Some patients stop every other asthma medicine once they feel better. This can leave airway inflammation untreated. Others continue despite distressing nightmares or depression because the connection to montelukast was not recognised early.
This is not for you if you have had a hypersensitivity reaction to montelukast or any component of the tablet.
Extra caution is needed if you have current depression, anxiety, severe insomnia or previous suicidal thoughts, or if you develop new behavioural or sleep symptoms after starting montelukast. Do not use Singulair to treat an acute asthma attack. Do not reduce or stop a prescribed inhaled corticosteroid without a clinician’s plan, even if asthma symptoms improve.
Many people tolerate montelukast without major problems. Headache, abdominal discomfort, thirst, diarrhoea, fatigue and upper respiratory symptoms have been reported. These effects are often mild, though persistent symptoms deserve review.
The most significant safety issue involves neuropsychiatric reactions. Reported effects include nightmares, vivid dreams, sleep disturbance, agitation, irritability, anxiety, low mood, behaviour changes and suicidal thoughts or actions. These reactions can occur in adults, adolescents and children.
The FDA strengthened its warning in 2020 after reviewing reports of serious mental health effects associated with montelukast. The warning advises careful benefit-risk consideration, especially when allergic rhinitis symptoms can be managed by other approaches. [3]
Seek urgent medical help for severe breathing difficulty, swelling of the face or throat, fainting, widespread rash, suicidal thoughts or marked behaviour change. Do not dismiss these symptoms as ordinary stress.
Singulair offers an oral anti-inflammatory route. It can be useful where allergic rhinitis and asthma overlap, or where a person struggles with inhaler technique. It does not replace inhaled corticosteroids when those are indicated for asthma control.
| Treatment approach | Main action | Typical role |
|---|---|---|
| Montelukast tablets | Blocks leukotriene receptors | Add-on prevention for asthma or allergic rhinitis |
| Inhaled corticosteroids | Reduces airway inflammation locally | First-line preventer treatment for persistent asthma |
| Antihistamines | Blocks histamine receptors | Relief of sneezing, itching and runny nose |
Inhaled corticosteroids remain central to asthma prevention because they treat airway inflammation directly in the lungs. Short-acting bronchodilators work quickly for acute symptoms but do not control the underlying inflammation. Antihistamines can ease itching and sneezing, yet they usually have less effect on wheeze or exercise-related bronchoconstriction.
NICE asthma guidance supports treatment plans built around symptom control, exacerbation risk and correct inhaler use, rather than a single medicine for every patient. [2]
A practical advantage of tablets is that no inhaler coordination is needed. The trade-off is that montelukast is not a rescue treatment and carries a specific mental health warning that needs attention.
In clinical practice, prescribers tend to see the clearest benefit from montelukast when asthma has an allergic or exercise-related pattern, or when allergic rhinitis adds to the respiratory burden. It can be a useful add-on, but it is rarely the entire asthma plan.
Doctors also ask direct questions about sleep, dreams, mood and behaviour. Patients may not volunteer these changes. They may attribute them to work pressure, family life or poor sleep habits. A precise timeline supports clinical review. Note when the tablet started, when symptoms appeared, and whether they eased after treatment changed.
The European Medicines Agency and MHRA product information emphasise monitoring for neuropsychiatric symptoms during montelukast treatment. [4]
Older adults can use montelukast when it is clinically appropriate, though their other medicines and health conditions need consideration. Liver function, multiple prescriptions and existing sleep or mood symptoms may influence the decision. The MHRA product information, updated in 2024, does not set an age-based exclusion for adults but supports individual prescribing assessment.
Some people notice fewer allergy symptoms or less night-time wheeze within days, while asthma control may take longer to judge reliably. The useful measure is a pattern over time: night waking, activity limitation, reliever inhaler use and flare-ups. NICE guidance from 2024 supports reviewing asthma response using symptoms and attack risk rather than judging success after a single dose.
Montelukast is generally prescribed as a once-daily treatment because its receptor-blocking effect is intended to provide day-to-day preventive coverage. It is not designed to give immediate rescue relief if the airways suddenly tighten. The FDA’s 2020 prescribing safety communication reinforces that acute asthma symptoms need appropriate rescue treatment, not reliance on montelukast alone.
Avoiding known triggers can reduce the inflammatory burden alongside prescribed treatment. Tobacco smoke, poor inhaler technique, untreated nasal allergies and irregular sleep may make asthma control harder to achieve. WHO asthma guidance published in 2023 highlights trigger reduction and consistent long-term management as part of controlling respiratory symptoms.
The duration depends on why Singulair was prescribed and whether it continues to improve symptoms without troublesome adverse effects. Some people use it through a defined allergy season, while others with chronic asthma remain on it longer with periodic review. The EMA and MHRA safety information available in 2025 supports ongoing reassessment of benefit, asthma control and mental health symptoms during prolonged treatment.
Montelukast does not usually require dose tapering because it does not cause physical dependence. Symptoms of asthma or allergic rhinitis may return if the medicine had been suppressing leukotriene-driven inflammation. A clinician should review the wider asthma plan before stopping it, since inhaled preventers or other treatments may still need adjustment. The MHRA product information from 2024 supports reviewing asthma control before treatment changes.
Singulair tablets can generally be taken with or without food. Taking it at a consistent time supports regular exposure and reduces missed doses. For people using it for asthma, evening dosing is often selected; the individual regimen should account for age, other medicines and health conditions. The MHRA product information from 2024 supports consistent administration according to the prescribed regimen.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Asthma can require long-term management. Some people use Singulair continuously when it contributes to stable symptom control, fewer night awakenings or reduced exercise-triggered symptoms. Others need it only during predictable allergy periods.
Long-term benefit should be reviewed against day-to-day asthma control, use of reliever medication, exacerbations and adverse effects. A tablet that helped during a severe pollen season may not remain necessary at the same intensity throughout the year. Treatment reviews also identify people who have quietly reduced or stopped their inhaled preventer.
There is no evidence that montelukast creates physical dependence. Continued use is based on clinical response, not withdrawal prevention.
I took Singulair every evening for several months alongside my usual inhaler. My spring cough settled and I was waking less often with chest tightness. I did not notice stomach problems, but I kept a note of my sleep because my prescriber had mentioned vivid dreams.
I used the tablets through the grass pollen season after my asthma became worse on runs. After about two weeks, I needed my reliever inhaler less often outdoors. I missed doses twice during a work trip and noticed the night cough returning, so I changed the reminder on my phone.
The breathing benefit was useful at first, but after several weeks I had unusually intense dreams and felt irritable in the mornings. I contacted my prescriber rather than carrying on. The timing mattered because those symptoms had started after the tablets.
